CEO, CFO and CSO increase their shareholdings in SynAct

SynAct Pharma AB (“SynAct”) hereby announces that three members of the company’s management have increased their respective holdings in SynAct.

SynAct Pharma AB (“SynAct”) hereby announces that three members of the company’s management have increased their respective holdings in SynAct. The company’s CEO, Jeppe Øvlesen, has purchased 9 071 shares for a total value of SEK 64 453, through a partly owned company, Quantasses ApS . The company’s CFO, Henrik Stage, has purchased 7 000 shares for a total value of SEK 48 263 through a wholly-owned company, Next Stage Ventures ApS. The company’s CSO, Thomas Jonassen, has purchased 9 200 shares for a total value of SEK 63 480 through a wholly owned company, TJ Biotech ApS . All shares have been purchased in the current trading on Aktietorget on 3 October 2017.

This is information that SynAct Pharma AB is obliged to disclose under the EU market abuse regulation. The information was submitted by the above contact person for publication on 6 October 2017. 


For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen                                                                                         Thomas Jonassen

CEO, SynAct Pharma AB                                                                   CSO, SynAct Pharma AB

Telephone: +45 28 44 75 67                                                           Telephone: +45 40 15 66 69
E-mail: joo@synactpharma.com                                                  E-mail: tj@synactpharma.com